You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Low HER2

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

HER2 Low Breast Carcinoma Trial (SHR-A1811 for injection)

Not yet recruiting
  • HER2 Low Breast Carcinoma
  • SHR-A1811 for injection
  • (no location specified)
Jun 12, 2023

Breast Cancer Trial (SHR-A1811 for injection ; capecitabine)

Not yet recruiting
  • Breast Cancer
  • SHR-A1811 for injection ; capecitabine
  • (no location specified)
May 4, 2023

Breast Cancer, Neoadjuvant Therapy Trial in Wuhan (Disitamab Vedotin combined with Tislelizumab)

Recruiting
  • Breast Cancer
  • Neoadjuvant Therapy
  • Disitamab Vedotin combined with Tislelizumab
  • Wuhan, Hubei, China
    WuhanHU
May 16, 2023

HER2-low in Unresectable and/or Metastatic Breast Cancer

Not yet recruiting
  • Breast Neoplasms, Breast Cancer, Breast Carcinoma, Genes, HER-2, Genes, HER2
    • (no location specified)
    Nov 6, 2023

    HER2-low in Metastatic Breast Cancer Patients

    Not yet recruiting
    • HER2-negative
      • (no location specified)
      Nov 9, 2023

      DESTINY Breast Respond HER2-low Europe

      Not yet recruiting
      • Unresectable Breast Cancer
      • +2 more
      • Trastuzumab deruxtecan
      • (no location specified)
      Jul 6, 2023

      Survival Rate of HER2-Low Breast Cancer Patients

      Completed
      • HER2 Low Breast Carcinoma
      • immunohistochemistry (IHC) and in situ hybridization (ISH) Test
      • (no location specified)
      Mar 2, 2023

      Clinical Outcomes in HR+ and HER2-low/Negative Breast Cancer

      Active, not recruiting
      • Hormone-receptor-positive Breast Cancer
      • +2 more
      • No drug
      • Cambridge, Massachusetts
        ConcertAI database
      Sep 8, 2023

      HER2-low Advanced Breast Cancer Patients Treated With ADC

      Recruiting
      • Breast Cancer
      • HER2 expression of circulating tumor cells
      • Beijing, Beijing, China
        The Fifth Medical Center of PLA General Hospital
      Apr 18, 2023

      Gastric Cancer, HER2-low-expressing Gastric Cancer Trial in Shanghai (Disitamab Vedotin, Toripalimab)

      Recruiting
      • Gastric Cancer
      • HER2-low-expressing Gastric Cancer
      • Shanghai, China
        Shanghai East Hospital
      Oct 9, 2023

      Breast Cancer Trial (Trastuzumab Deruxtecan)

      Not yet recruiting
      • Breast Cancer
      • Trastuzumab Deruxtecan
      • (no location specified)
      Jul 10, 2023

      Stomach Tumor Trial (Trastuzumab deruxtecan, Afatinib)

      Not yet recruiting
      • Stomach Neoplasm
      • (no location specified)
      Oct 16, 2023

      HER2-positive Breast Cancer Trial (Standard of Care Adjuvant Breast Radiation, Standard of Care HER2-targeted Therapy Without

      Not yet recruiting
      • HER2-positive Breast Cancer
      • Standard of Care Adjuvant Breast Radiation
      • Standard of Care HER2-targeted Therapy Without Adjuvant Breast Radiation
      • (no location specified)
      Jan 20, 2023

      Breast Cancer Invasive, Hormone-receptor-positive Breast Cancer, HER2 Low Breast Carcinoma Trial in Guangzhou (Pyrotinib,

      Not yet recruiting
      • Breast Cancer Invasive
      • +3 more
      • Pyrotinib, epirubicin or doxorubicin, cyclophosphamide, paclitaxel
      • Placebo, epirubicin or doxorubicin, cyclophosphamide, paclitaxel
      • Guangzhou, Guangdong, China
        Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
      Nov 17, 2023

      Advanced Breast Cancer Trial (Disitamab vedotin)

      Not yet recruiting
      • Advanced Breast Cancer
      • Disitamab vedotin
      • (no location specified)
      Apr 16, 2023

      Her2-positive/Low-expression Urinary and Digestive Tract Tumors Trial in Beijing (BL-M07D1)

      Not yet recruiting
      • Her2-positive/Low-expression Urinary and Digestive Tract Tumors
      • Beijing, Beijing, China
        Cancer Hospital, Chinese Academy of Medical Sciences
      Sep 8, 2023

      Breast Cancer Trial (Disitamab Vedotin+Anlotinib)

      Not yet recruiting
      • Breast Cancer
      • Disitamab Vedotin+Anlotinib
      • (no location specified)
      Aug 14, 2023

      HR Positive/HER2 Low Expression Metastatic Breast Cancer Trial in Guangzhou, Shantou, Qionghai (Disitamab vedotin, Endocrine

      Recruiting
      • HR Positive/HER2 Low Expression Metastatic Breast Cancer
      • Disitamab vedotin
      • Endocrine therapy
      • Guangzhou, Guangdong, China
      • +2 more
      Jun 19, 2023

      HER2 Low Advanced or Metastatic Breast Cancer Trial (SHR-A1811 & Dalpiciclib Isethionate Tablets, SHR-A1811 & Fulvestrant,

      Not yet recruiting
      • HER2 Low Advanced or Metastatic Breast Cancer
      • SHR-A1811 & Dalpiciclib Isethionate Tablets
      • +2 more
      • (no location specified)
      Mar 19, 2023

      Invasive Breast Cancer, Inflammatory Breast Cancer Stage III, HER2-positive Breast Cancer Trial in Boston (Trastuzumab

      Not yet recruiting
      • Invasive Breast Cancer
      • +4 more
      • Boston, Massachusetts
      • +1 more
      Mar 20, 2023

      Breast Cancer Trial in Shanghai (SHR-A1811, TROP2 ADC)

      Active, not recruiting
      • Breast Cancer
      • Shanghai, China
        Fudan University Shanghai Cancer Center
      Apr 11, 2023

      Breast Cancer, Metastatic Breast Cancer Trial (Trastuzumab-Deruxtecan (T-DXd))

      Not yet recruiting
      • Breast Cancer
      • Metastatic Breast Cancer
      • Trastuzumab-Deruxtecan (T-DXd)
      • (no location specified)
      Sep 20, 2023

      Breast Cancer Trial in Houston (Trastuzumab deruxtecan, Valemetostat)

      Not yet recruiting
      • Breast Cancer
      • Houston, Texas
        M D Anderson Cancer Center
      Dec 14, 2022

      Colorectal Cancer Trial (Anti-HER2 ADC)

      Not yet recruiting
      • Colorectal Cancer
      • Anti-HER2 ADC
      • (no location specified)
      Oct 12, 2022

      Triple-Negative Breast Cancer Trial in Shanghai (Trastuzumab Deruxtecan)

      Not yet recruiting
      • Triple-Negative Breast Cancer
      • Trastuzumab Deruxtecan
      • Shanghai, Shanghai, China
        Breast cancer institute of Fudan University Cancer Hospital
      Jul 12, 2023